Nearly 90% of patients with hypercalcemia have primary hyperparathyroidism or malignancy.
Nearly 90% of patients with hypercalcemia have primary hyperparathyroidism or malignancy. There is a wide spectrum of clinical features since hypercalcemia affects neurologic, gastrointestinal, cardiovascular, and renal function. Specifically with malignancy-related hypercalcemia, the pathophysiology derives from excessive parathyroid hormone-related protein, osteolytic metastases, or formation of calcitriol. Confirm hypercalcemia with an ionized calcium. Most cases of mild to moderate hypercalcemia are self-limiting or can be managed with volume repletion. For more moderate to severe patients is life-threatening and hydration alone is inadequate. Let’s open the drug bank. Two options deposited. Calcitonin and zolendronic acid. Calcitonin decreases bone resorption and increased urinary excretion of calcium. It is given IM or SUBQ. Zolendronic acid, an IV biphosphate, reduces osteoclast activity and calcium release from tumors. Caution with renal impairment as this increases risk of nephrotoxicity and symptomatic hypocalcemia. Sounds like you need to consult a pharmacist. For more PHARMFAX in the drug bank, check out another video on my page, and I hope you learned something new.
The All PHARYMWZE Source (including references)
www.pharmwyze.com
Follow @pharmwyze on your favorite social media platform
#hypercalcemia #zolendronicacid #calcitonin #emergencymedicine #criticalcare #pharmfax #pharmwyze #drugbank #medicine #nursing
Not medical advice. Educational purposes only. No relationships to report. I hope you learned something new.
Commentaires